Travere Therapeutics, Inc. (TVTX): auditor change — Travere Therapeutics dismisses BDO as auditor, appoints EY; discloses material weakness in internal controls

Travere Therapeutics, Inc.

BDO dismissed as independent auditor effective April 6, 2023; EY appointed for fiscal year ending Dec 31, 2023.
BDO's audit reports for FY2022 and FY2021 were unqualified with no adverse opinion or modifications.
Disclosed material weakness in controls over pre-launch inventory contract affecting R&D expense timing; no restatement required.
No disagreements with BDO on accounting principles or audit scope during 2022, 2021, or interim period through April 6, 2023.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Travere Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

the Audit Committee approved the appointment of EY as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Travere Therapeutics, Inc. dismissed BDO USA, LLP as its auditor.

Action: dismissal
Auditor: BDO USA, LLP

Exact text from the filing

On April 6, 2023, the Audit Committee dismissed BDO as the Company’s independent registered public accounting firm.

View on SEC.gov

21 auditor changes filed in the last 30 days. Browse all auditor changes →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.